Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab vs Denosumab in Glucocorticoid-induced Osteoporosis at 6 Years
NCT07757373Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
- Sponsor
- Tuen Mun Hospital
- Drugs
- romosozumab
- Conditions
- glucocorticoid-induced osteoporosis (GIOP)
01
Overview
Phase 4, randomised, open-label trial of romosozumab in glucocorticoid-induced osteoporosis (GIOP) (2 arms), sponsored by Tuen Mun Hospital. Primary endpoint: Bone mineral density at 6 years. Planned start Sep 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
romosozumab
romosozumab for 12 months, followed by denosumab
denosumab alone
denosumab alone
03
Who it enrols
Patients from the original study who are continued on 6-monthly subcutaneous denosumab after month 48, willing to have a repeat DXA at 6 years, and not planning to taper or discontinue prednisolone.
04
Endpoints
Primary
Bone mineral density
Beyond the preview
Go deeper on NCT07757373.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757373.